Valuation: Ovoca Bio plc

Capitalization 1.11M 1.28M 996K 957K 1.74M 118M 1.83M 11.78M 4.71M 56.56M 4.82M 4.71M 203M P/E ratio 2023
-0.18x
P/E ratio 2024 -2.12x
Enterprise value -1.4M -1.63M -1.26M -1.21M -2.21M -150M -2.31M -14.93M -5.97M -71.7M -6.11M -5.98M -257M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
55.33%
Yield 2023 *
-
Yield 2024 -
Change 5d. change 1-year change 3-years change Capi.($)
-.--%-.--% - - 7.82M
-0.61%-4.57%+5.07%+91.15% 44.3B
+0.92%-4.81%+55.76%+12.07% 40B
-2.40%-6.58%+80.70%+580.24% 30.95B
-0.44%-6.71%-11.56%-22.38% 25.58B
+2.54%-5.07%+57.32%-37.07% 18.76B
-2.62%-5.78%+4.47%-32.53% 16.89B
+5.20%+5.30%+46.09%+144.70% 12.02B
+1.14%-4.37%-22.71%+881.17% 11.58B
+4.43%+1.36%+59.06% - 11.03B
Average +0.82%-4.04%+30.46%+202.17% 23.46B
Weighted average by Cap. +0.25%-4.13%+31.97%+162.97%

Financials

2023 2024
Net sales - -
Net income -4.7M -5.46M -4.24M -4.07M -7.41M -502M -7.77M -50.12M -20.04M -241M -20.5M -20.06M -862M -746K -867K -672K -646K -1.18M -79.68M -1.23M -7.95M -3.18M -38.18M -3.25M -3.18M -137M
Net Debt -3.34M -3.88M -3.01M -2.89M -5.26M -356M -5.51M -35.57M -14.23M -171M -14.55M -14.24M -612M -2.51M -2.91M -2.26M -2.17M -3.95M -268M -4.14M -26.71M -10.68M -128M -10.92M -10.69M -459M
Logo Ovoca Bio plc
Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.
Employees
-